Found: 15
Select item for more details and to access through your institution.
Zongertinib Demonstrates Clinically Meaningful Efficacy in HER2-Mutated NSCLC.
- Published in:
- OncologyLive, 2024, v. 25, n. 15, p. 64
- By:
- Publication type:
- Article
Novel Perioperative Combinations Show Efficacy in Resectable NSCLC.
- Published in:
- OncologyLive, 2024, v. 25, n. 15, p. 63
- By:
- Publication type:
- Article
Ivonescimab Outperforms Pembrolizumab as Frontline Therapy in PD-L1+ Advanced NSCLC.
- Published in:
- OncologyLive, 2024, v. 25, n. 15, p. 60
- By:
- Publication type:
- Article
Taletrectinib Shows Consistent Efficacy, Safety in ROS1+ NSCLC Independent of Prior TKI Exposure.
- Published in:
- OncologyLive, 2024, v. 25, n. 15, p. 58
- By:
- Publication type:
- Article
Discussions Swirl on the Role of PD-1 Inhibitors for Gastric/GEJ/ESCC Cancers With 1%-10% PD-L1 Expression.
- Published in:
- OncologyLive, 2024, v. 25, n. 15, p. 52
- By:
- Publication type:
- Article
Education, Telehealth, and Access Initiatives Aim to Improve Cancer Care for Veterans.
- Published in:
- OncologyLive, 2024, v. 25, n. 15, p. 48
- By:
- Publication type:
- Article
THE MICROBIOME AND COLON CANCER: Dietary Influence on Incidence, Morbidity, and Mortality.
- Published in:
- OncologyLive, 2024, v. 25, n. 15, p. 46
- By:
- Publication type:
- Article
First-in-Class Bicycle Toxin Conjugate Targeting Nectin-4 Generates Excitement in Urothelial Carcinoma.
- Published in:
- OncologyLive, 2024, v. 25, n. 15, p. 43
- By:
- Publication type:
- Article
Adding an HPK1 Inhibitor to Immune Checkpoint Inhibition May Be Effective in Solid Tumors.
- Published in:
- OncologyLive, 2024, v. 25, n. 15, p. 36
- By:
- Publication type:
- Article
An Era of Firsts in CML: Asciminib Challenges SOC TKIs.
- Published in:
- OncologyLive, 2024, v. 25, n. 15, p. 30
- By:
- Publication type:
- Article
Obe-Cel May Expand CAR T-Cell Therapy Options in Relapsed/Refractory ALL.
- Published in:
- OncologyLive, 2024, v. 25, n. 15, p. 22
- By:
- Publication type:
- Article
Adjuvant Ribociclib Expands Access to CDK4/6 Inhibition in High-Risk HR+/HER2-- Breast Cancer.
- Published in:
- OncologyLive, 2024, v. 25, n. 15, p. 14
- By:
- Publication type:
- Article
FDA Digest.
- Published in:
- OncologyLive, 2024, v. 25, n. 15, p. 12
- Publication type:
- Article
CANCER CLINICAL TRIALS: A Relevant Need to Clearly Define the Value to Individual Patients.
- Published in:
- OncologyLive, 2024, v. 25, n. 15, p. 10
- By:
- Publication type:
- Article
New Research Aims to Improve Cancer Care in All Sectors.
- Published in:
- OncologyLive, 2024, v. 25, n. 15, p. 8
- By:
- Publication type:
- Article